Drug intelligence / Profile preview

N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-amine

Development stage: Unknown
Modality: Small Molecules

Overview

This compound is an experimental small molecule belonging to the quinazoline class of drugs. It features a quinazoline core substituted with a 5-chloro-benzodioxole group and a 6-methoxy and 7-propoxypiperidine moiety. The compound has been identified as an inhibitor of several receptor tyrosine kinases including Ephrin type-B receptor 4 (EPHB4), Fibroblast growth factor receptor 1 (FGFR1), Vascular endothelial growth factor receptors VGFR1 and VGFR2, and SRC kinase. These targets are implicated in angiogenesis and cancer cell signaling pathways. The drug is not approved for any indication and remains at the experimental stage[2][8].

Other names: N-(5-chloro-2H-1,3-benzodioxol-4-yl)-6-methoxy-7-[3-(piperidin‑1‑yl)propoxy]quinazolin‑4‑amineN-(5-Chlorobenzo[d][1,3]dioxol‑4‑yl)-6-methoxy‑7-(3-piperidin‑1‑ylpropoxy)quinazolin‑4‑amine(5-Chloro-benzo[1,3]dioxol–4–yl)-(6-methoxy–7–(3-piperidin–1–yl-propoxy)–quinazolin–4–yl)-amine

Targets

EPHB4 (Ephrin type-B receptor 4)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)SRC (Proto-oncogene tyrosine-protein kinase Src)

Beyond the preview

Go deeper on N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-amine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-amine.

Explore the full profile